Two Deals Bolster Watson's Position In Branded Women's Health Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Branded drugs may earn only a fraction of Watson's generics, but firm sees overlapping opportunity in urology and women's health care.
You may also be interested in...
Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.
Watson Biosimilar Tie Up With Itero Plays Into Women's Health Expertise
Watson licenses rights to a recombinant follicle stimulating hormone in preclinical development that would reference Merck-Serono's infertility drug Gonal-f.
Watson Biosimilar Tie Up With Itero Plays Into Women's Health Expertise
Watson licenses rights to a recombinant follicle stimulating hormone in preclinical development that would reference Merck-Serono's infertility drug Gonal-f.